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The sequence of the Vu gene of a monoclonal anti-biotin antibody was determined. Biotin-binding motifs, similar to those in avidin and streptavidin, 
were identified in complementarity determining regions 2 and 3, suggesting that natural selection of functional motifs may occur in unrelated protein 
types. 
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1. INTRODUCTION 
The avidin-biotin complex is the epitome of biologi- 
cal recognition processes [1,2]. Knowledge of the inter- 
actions which participate in the formation of this com- 
plex may eventually lead to a better understanding of 
the interaction between proteins and ligands in general. 
Recently, we have succeeded in elucidating the three- 
dimensional structure of egg white avidin and its com- 
plex with biotin [3]. Comparison with the known struc- 
ture of its bacterial relative, streptavidin [4,5], has re- 
vealed that the overall fold of the two proteins is very 
similar. The close similarity also applies to most of the 
residues in the respective binding sites which are crucial 
for interaction with the biotin molecule. Interestingly, 
the similarity in binding can be traced to individual 
amino acid residues which occupy defined positions in 
six homologous stretches of the two proteins [6,7]. Thus, 
although the overall homology in the primary structures 
of avidin and streptavidin is only 30% (43% similarity), 
the extent of homology within these homologous 
stretches is 65% (80% similarity). 
tionary time-frame of millions of years. It was of inter- 
est to us to consider a contrasting situation, where a 
biotin binding site exists in a different type of molecule, 
e.g. an antibody. When the biotin moiety is covalently 
attached to a foreign carrier protein, anti-biotin anti- 
bodies are elicited. We thus questioned whether the im- 
mune system would select he same type of elements (i.e. 
the same amino acids) to produce a biotin binding site 
in an antibody as those which are known to recognize 
biotin in the binding site of avidin. 
In order to address this question, we produced mon- 
oclonal anti-biotin antibodies, which bind the vitamin 
with a relatively high affinity (KA - 10’ M-‘). We report 
here the cloning and sequencing of the V, cDNA of this 
antibody. Comparison of the sequence of Vn with those 
of avidin and streptavidin revealed an astonishing simi- 
larity in the CDR2 and CDR3 regions of the antibody 
with known biotin binding motifs in two of the homol- 
ogous stretches of avidin and streptavidin. 
2. MATERIALS AND METHODS 
These findings have prompted us to consider whether 
such a high-affinity interaction is simply an accident of 
nature or whether it reflects the product of evolutionary 
design. In this context, the biotin binding sites of avidin 
and streptavidin were contrived throughout an evolu- 
2.1. Reagents and solutions 
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Tris-(hydroxymethyl)-aminomethane, bovine serum albumin (BSA, 
RIA grade), Tween 20, diethylene triamine pentaacetic acid (DTPA), 
bovine y-globulin, incomplete and complete Freund’s adjuvant, l- 
ethyl-3(3-dimethyl aminopropyl) carbodiimide (WSC, water-soluble 
carbodiimide), poly+lysine (M, 15,000-30,000) and ovalbumin were 
purchased from Sigma Chemical Co. (St. Louis, MO). Affinity-puri- 
fied rabbit anti-mouse immunoglobulin was obtained from Da- 
kopatts, Glostrup, Denmark. Sepharose-protein A and Sephadex G- 
25 were products of Pharmacia, Uppsala, Sweden. Anti-mouse immu- 
noglobins (used for Ouchterlony immunodiffusion) were from Serotec 
(Oxford, UK). The labeling reagent [N-l-(p-isothiocyanatophenyl) 
diethylene triamine-N’,N2,N3-tetraacetate (DTTA)], chelated with 
Eu3’, was kindly provided by Dr. Iikka Hemmila, Wallac Oy, Turku, 
Finland. 
Coating buffer for ELISA plates consisted of 50 mM sodium car- 
bonate, pH 9.6, containing 0.02% sodium azide. Time-resolved fluo- 
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rescence was measured using the enhancement solution obtained from 
Wallac, Oy. The assay buffer was 50 M Tris-HCl buffer, pH 7.75, 
containing BSA (5 g/l), bovine y-globulin (0.5 g/l), 20pmol of DTPA, 
sodium chloride (9 g/l), Tween 20 (0.5 ml/l) and sodium azide (0.5 g/l). 
Biotinylated BSA was prepared using biotin A’-hydroxysuccinimide 
ester [8]. 
2.2. Preparation of europium-labeled reagents 
Biotin was conjugated to polylysine using the WSC coupling proce- 
dure [8]. The resultant derivative (1 mg/ml) was dialyzed for 2 h against 
50 mM carbonate buffer, pH 9.8, and derivatized further with euro- 
pium-chelated DTTA, as described previously [9]. 
2.3. Preparation of monoclonal anti-biotin antibodies 
Female, 2-month-old CB6/black mice were immunized with bioti- 
nylated BSA (50 pg/mouse) in complete Freund’s adjuvant. Subse- 
quently, two booster injections were given, using the biotinylated BSA 
preparation in incomplete Freund’s adjuvant. After a 2-month immu- 
nization period, the antibody titer was checked using rabbit anti- 
mouse IgG-coated plates (prepared as described previously [lo], euro- 
pium-chelated biotin-polylysine as a label, and time-resolved fluores- 
cence as an end point [9,10]). Three months after the initial immuniza- 
tion, spleen cells of the mouse were selected on the basis of their 
interaction with the europium-chelated biotin-polylysine preparation. 
Those which exhibited the highest serum titer of antibody which rec- 
ognized the biotin-containing label were fused with a mouse myeloma 
cell line (NSO, kindly donated by Dr. C. Milstein, Cambridge), using 
the hybridoma technique of Kiihler and Milstein [ll]. The culture 
supernatants ofgrowing hybridomas were screened for antibody activ- 
ity using rabbit anti-mouse IgG-coated plates, and the europium- 
chelated biotin-polylysine. Four hybridomas were selected; the clone 
(Fl) which demonstrated the highest affinity for biotin was propa- 
gated in vitro and used to prepare RNA. 
2.4. Cloning of the gene for the VH region of monoclonal anti-biotin 
The F, hybridoma cell line which secreted anti-biotin antibodies 
(IgG,) was grown in Dulbecco’s modified Eagle’s medium, supple- 
mented with 10% (v/v) horse serum. Total cellular RNA was prepared 
from F, cells (5 x 106) using the Nonidet P-4O/SDS technique as de- 
scribed by Gough [12]. Poly(A)-containing RNA was purified by affin- 
ity chromatography over magnetic oligo(dT) [13]. First-strand DNA 
10 
synthesis was performed by incubating poly(A) mRNA (- 0.1 pg) at 
37’C for 90 min with a mixture of 50 mM of Tris-HCl, pH 8.3,50 mM 
KCl, 10 mM MgCl,, 10 mM dithiothreitol, RNase inhibitor, 1 mM 
deoxynucleotides, 2.5 ng of oligo(dT),, as primer and AMV reverse 
transcriptase in a reaction volume of 6Ofil.10~1 of the cDNA reaction 
mixture were used directly in a PCR, using 2.5 U Taq DNA polym- 
erase with 25 pmol of the mouse Vu forward primer (5’-TGAGGA- 
GACGGTGACCGTGGTCCCTTGGCCCC) and 25 pmol of the 
mouse Vu backward primer (5’-AGGT(UG)(A/C)A(A/G)CTGC- 
AG(C/G)AGTC(A/T)GG), and deoxynucleotides in Taq buffer [14]. 
The mixture was amplified for 30 cycles and an ethidium bromide- 
stained 2% agarose gel was used to visualize the PCR fragments. The 
amplified product was purified by electroelution, and blunt ended with 
Klenow enzyme and T4 polynucleotide kinase. The DNA product was 
inserted into pBluescriptKS vector which was digested with SmaI and 
dephosphorylated. The ligation mixture was used to transform E. coli 
TGl competent cells, and transformants were selected on LB plates, 
containing ampicillin, IPTG and X-Gal. From the resulting colonies, 
DNA minipreparations were performed; the size of the inserts were 
analyzed by an A’baIlSalI digestion. Clones containing inserts of the 
correct size (approximately 350 bp) were grown in 5 ml TB medium. 
Following growth, cells were collected by centrifugation and lysed. 
The supernatant was then decanted into a Magic minicolumn 
(Promega), and plasmid DNA was eluted according to the procedure 
recommended by the manufacturer. The purified DNA (approxi- 
mately 0.5pg) was sequenced on an ABI 373 DNA sequencer (Applied 
Biosystems Inc.), using SK or KS primer and cycle-sequencing reac- 
tions [I 51. 
3. RESULTS AND DISCUSSION 
In this study, a biotin-specific monoclonal antibody 
was elicited, its Vn gene was cloned and sequenced. The 
sequence is presented in Fig. 1. Upon comparing this 
sequence with those of avidin and streptavidin, we no- 
ticed that the CDR2 and CDR3 regions of the antibody 
show a startling resemblance to two homologous 
stretches in avidin and streptavidin which are known to 
interact with the bicyclic ring system of biotin (see Fig. 
20 
Q V KLQESGPGLVAPSQSLSI 
CAGGTQAAGCTG CAD GAGTCAGGACCTGGC CTGGTGGCCCCCTCACAGAGCCTGTCCATC 
TCTVSC PSL:~WVYQ~ 
ACT TGCACT GTCTCTGGG TTTTCATTAACCGCC TATGGTGTAGACTGG GTTCGCCAGCCT 
50 CUR2 I)0 
P QKCLE w L c v I WQQQRTIYW 
CCA GGAAAG GGTCTG GAG TGGCTGGGAGTAATATGGGGTGGTGGACGCACAAATTATAAT 
S~LX19RLSI~KDASXSQV~~ 
TCA GGTCTC ATGTCCAGACTGAGCATCAGGAAAGAC AACTCCAAGAGCCAAGTTTTCTTA 
80 
Y N s L QTDDTAKYY C V K IR~--~i ‘: 
ACA ATG MC AGT CTG CAA ACT GAT GAC ACA GCC MD TAT TAC TGT GTCAAA CAT ACG AAC 
W D Q Q F VTVSS 
TGG GACGGGGQG TTT GCTTACTGGGGCCMGGGACCACG GTCACCGTCTCCTCA 
Fig. 1. Nucleotide and deduced amino acid sequence of the V, gene of the anti-biotin antibody. Single-letter amino acid codes are used. The 
complementarity-determining re ions are indicated by shaded areas. The numbering is according to Kabat et al. [16]. 
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Fig. 2. Aliment of the amino acid sequences of complementa~ty- 
determining regions 2 and 3 of the anti-biotin antibody with relevant 
homologous tretches of avidin (Av) and streptavidin (StAv). Identical 
residues are denoted by vertical bars and similar conserved residues 
are indicated by dots. Identity in the antibody is emphasized by shad- 
ing. Amino acid residues in the binding sites of avidin and streptavidin, 
which are known to interact with the bicyclic ring of the biotin mole- 
cule, are shown in white lettering. The second and fourth homologous 
stretches of avidin and streptavidin encompass the 83 and /?6 strands 
of the two proteins. 
2). Specifically, the second homologous stretch of avidin 
and streptavidin (which encompasses the ,&3 strand of 
both proteins) contains the sequence xxxYxT(S)xx, and 
the CDR2 of the heavy chain of the antibody contains 
RTNYNSOL. Similarly, the fourth homologous stretch of 
avidin and streptavidin (which encompasses the j?6 
strand) contains the sequence xxTxF(W)xG, and the 
CDR3 of the antibody heavy chain contains HTNWDG. 
These results seem to indicate a similar pattern in the 
sequences which may dictate the quality of binding bio- 
tin. 
A comparison of the sequences of the ~omplementar- 
ity-determining regions of different antibodies, depos- 
ited in the SWISS-PRO?: protein data bank (Release 
23), revealed that the sequence, YNS, is very common 
in the CDR2 of the heavy chain. On the other hand, we 
could not find the sequence TxWxG in any other CDR3 
of known antibody sequence. 
These findings may indicate two separate principles. 
On the one hand, nature does not always have to pro- 
duce new functional motifs in order to produce a bind- 
ing site, since the YxS theme of the CDR2 is adequate 
for binding the ureido ring of the biotin moiety. Indeed, 
in both avidin and streptavidin, this particular con- 
served tyrosine-containing stretch has been shown to be 
decisive for the binding of biotin [17,18]. On the other 
hand, a new motif was introduced into the CDR3 of the 
antibody, presumably to reinforce the binding. Interest- 
ingly, in both avidin and streptavidin, this conserved 
motif is located near the thiophene ring of biotin; if 
future X-ray analysis of the antibody confirms the pres- 
ence of such a set of interactions, we may conclude that 
in nature such functional elements can be used for a 
given purpose irrespective of the protein type (i.e. avidin 
or antibody). 
This phenomenon may thus be an example of conver- 
gent evolution at the molecular level. The veracity of 
this notion is supported by the production of monoclo- 
nal antibodies against the fibrinogen binding receptor 
on platelets, in which the CDR3 of the heavy chain 
contains an RYD sequence which mimics the RGD 
motif of various adhesion proteins of the extracellular 
matrix [X9]. These results also underscore the salience 
of the CDR3 in antigen recognition. 
Finally, our findings may pave the way for a new 
approach to engineering of specific combining sites on 
antibodies. Known binding sites from other proteins 
can thus be transferred to an appropriate CDR region 
of an appropriate antibody. For example, the IO-12 
residue bungarotoxin binding site of the acetylcholine 
receptor has been incorporated into a chimeric protein 
from E. cd& and the resultant protein exhibits bungaro- 
toxin binding activity [ZO]. Insertion of this peptide into 
the CDR3 of the V, of a carrier immunoglobulin may 
thus impart the quality of bungarotoxin binding in an 
antibody. Likewise, catalytic antibodies may be pro- 
duced by transferring known binding and catalytic sites 
from enzymes to the CDRs of an antibody molecule. 
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